A senior lender called the loan at month 11 and the gap piece had no notice right in the paper

The cure-and-acceleration cycle is the part that deserves more attention here. Even if the gap lender funds the cure and stops the foreclosure clock, a hard money bridge with a covenant default already triggered is a lender looking for the exit, and most of those notes carry broad enough default language that a second technical breach is easy to manufacture or find. The gap lender would be wiring good money into a position where the senior holds an option to accelerate at will, with no standstill obligation in place, which means the cure buys time but not safety.

The piece that changes the math is subrogation. If the gap lender funds the cure, they should simultaneously be demanding a written subrogation agreement from the borrower that converts that cure payment into a senior-priority advance, stepping into the senior lender's position to the extent of the cure amount. Without that, the cure money lands in second position behind the 310k balance and earns no better recovery than the original 60k. A properly papered subrogation clause in the intercreditor, or a standalone agreement executed at cure, is what separates a defensive move that preserves capital from one that simply delays the loss.

The 80k equity buffer between the 390k value and the 370k combined debt looks sufficient on paper, but hard money lenders in foreclosure routinely tack default interest at 18 to 24 percent, attorney fees, and receiver costs, and those accrue against the senior balance first. On a 310k note at 24 percent default rate, six months of fees and interest adds roughly 40k, which compresses that buffer to the point where a distressed foreclosure sale at even a modest discount wipes out the second position entirely.

What was the stated value based on, a completed ARV or the as-is value at month 11 of the reh

The assumption doing the most work in that deal was that 80k of apparent equity (390k value minus 310k senior balance) constituted meaningful protection for a subordinate position. It did not, because equity in a distressed foreclosure is not the same thing as equity in a clean sale. Foreclosure fees, senior lender default interest, attorney costs, and timeline compression can consume that buffer in a way that a static LTV calculation at origination never shows. A second position on a 79% combined LTV bridge deal with no intercreditor protection is a different instrument than that number suggests.

The cure mechanics deserve the scrutiny you flagged. When a junior lender funds a cure on a senior default, they are not improving their position in any structural sense. They are extending capital to protect collateral that the senior still controls, under a note the senior can accelerate again on any subsequent covenant breach. Depending on how the gap lender's documents are drafted, that cure advance may or may not tack onto the secured position, and whether it does requires a look at the specific loan documents and applicable state law. A real estate attorney needs to answer that question before the wire goes, not after.

The intercreditor point is the one I would pull forward. A senior hard money lender who refuses to execute an intercreditor is communicating something important about how they intend to operate if the deal deteriorates. That refusal is data about the actual risk of the second position, and pricing or declining accordingly is the appropriate response. A notice-and-cure right is not a favor the senior grants. It is a condition the gap lender sets before closing.

The procedural gap here, no independent notice, no standstill, no defined cure window, is a drafting failure that due diligence should catch before the gap piece funds.

What did the gap lender's own term sheet specify as a condition to closing, and did it require a fully executed intercreditor or leave that as a best-efforts obligation?

The line about seniors refusing to sign an intercreditor entirely is the one I needed to see spelled out like that. I had assumed it was a negotiation with a landing point, not a hard no that still lets the deal close.

What I cannot figure out is why the gap lender funded without it. Was there anything in their term sheet that required intercreditor execution as a closing condition, or did they just skip it because the equity cushion looked wide enough on paper?

The equity math here is the part that deserves more pressure. At 310k senior plus 60k gap against a 390k mid-rehab value, the loan-to-value looks survivable on paper, but that 390k is a contractor's or broker's estimate during construction, which means it is the number most likely to compress exactly when you need it to hold. Foreclosure sale discounts on incomplete rehabs regularly run 15 to 25 percent below stabilized ARV, and senior fees plus attorney costs on a contested timeline can add another 8 to 12 percent drag before second position sees a dollar. The gap lender's real cushion was probably thinner than the headline spread suggested.

The related structure worth considering is a completion guarantee tied to the gap piece, because the scenario you described is really a construction risk problem wearing a bridge lending costume. If the gap term sheet had required the borrower to maintain a funded interest reserve with the gap lender, and tied any disbursement from that reserve to a monthly confirmation that the senior was current, the gap lender would have had an early signal rather than a foreclosure notice. That is a contractual substitute for the intercreditor notice right, imperfect but available even when the senior refuses to sign anything formal.

What was the stated exit on the gap piece, and did the term sheet require any confirmation that the takeout refinance was actually committed before the gap funds were released?

When did the gap lender first see the senior loan docs?

Foreclosure sale proceeds do not go to junior lienholders after fees; they go to the senior balance first, then fees, then junior, and "enough equity" shrinks fast once you add receiver costs, attorney fees, and sale costs that routinely run 8 to 12 percent of the senior balance on a hard money foreclosure. The cure option is worse than it looks because curing a covenant default, rather than a payment default, often does not reset the senior's acceleration right, so the gap lender may wire money into a loan the senior has already decided to exit, buying days rather than the remaining term. The intercreditor gap is real, but the deeper problem is that a covenant-triggered call at month 11 on a 14-month bridge suggests the senior had a contractual exit they wanted, and no intercreditor provision prevents a lender from enforcing a legitimate covenant breach, it only guarantees the junior gets notice and a cure window, which is valuable but does not cure the underlying default if the breach is not curable by a third party. What was the covenant that triggered the call, because if it was a completion milestone or a loan-to-cost test, the gap lender could not have cured it regardless of what the intercreditor said?

The cure math compounds the problem in a way the equity cushion masks at first glance. Say the gap lender wires the cure payment, call it 8k to bring the senior current, and the senior calls the note again at month 13 for a different covenant breach. The gap lender has now spent 8k to buy roughly 60 days, still holds a second position with no standstill protection, and the senior's accumulated fees have already trimmed the 80k equity buffer by a third. The effective collateral supporting that 60k gap piece is no longer 80k, it is whatever survives the senior's fee schedule, the foreclosure filing costs, and the sale discount a distressed auction typically produces, which on a 390k property in mid-rehab can run 10 to 15 percent below as-is value.

The procedural question I would want answered is whether the gap lender's own term sheet made an executed intercreditor a condition of funding, or whether it was listed as a "preferred" document and then waived when the deal came together quickly. That distinction matters because a gap lender who funded without a mandatory intercreditor requirement has a process problem, not just a document problem, and the next deal has the same exposure unless the term sheet language changes.

What did the gap lender's commitment letter actually say about intercreditor execution as a funding condition?

Sixty thousand behind a lender who can call the note for any covenant breach and then call it again after you cure is not a second position, it is a donation with paperwork.

What I have never seen work is the "enough equity on paper" argument once fees start running. Senior legal costs, trustee fees, and timeline drag turned a theoretical 80k cushion into a real 12k argument in a deal I watched in Scottsdale last spring, and that was a clean title situation. What happens instead is the gap lender negotiates after the fact from the worst possible position, which is no leverage and a ticking clock.

Was the gap lender a private individual or an actual fund, because a fund doing 60k seconds without intercreditor language in the term sheet as a hard requirement is a process failure, not a documentation oversight.

The question about the term sheet is the right one, but the step before it matters more: whether the gap lender's own documents required an executed intercreditor as a condition to funding, or just encouraged the borrower to obtain one. If it was a covenant rather than a condition precedent, the gap lender funded into a structure it had already decided to accept without the protection, which is a different kind of exposure than being ambushed after closing. What did the gap piece actually condition disbursement on?

The misconception worth correcting: funding a cure does not reinstate your lien priority or give you any claim against the senior for the capital you spent, it simply buys time on a clock the senior still controls.

The detail that changes the cure calculus here is whether the gap lender's $60k piece carried any subrogation language. If the intercreditor had been properly drafted with a subrogation right, the gap lender curing a senior default would step into the senior's position for the cured amount, which converts that out-of-pocket spend from a defensive cost into secured debt sitting at first-position priority for that slice. Without subrogation language, the $60k lender wires money to cure, remains in second position, and the senior can accelerate again on the next technical breach with no obligation to notify anyone or wait. That is the structural failure underneath the equity math: $80k of cushion at that stage of rehab sounds survivable until you price in the senior's per diem fees, a foreclosure attorney running the clock at $400 to $600 an hour in most jurisdictions, and any cost-to-complete exposure if the property is mid-construction when the sale is noticed. The buffer compresses faster than a static LTV calculation suggests. What was the rehab completion percentage at month 11, because that number moves the as-is sale value and the senior's fee accrual in opposite directions simultaneously?

A redemption right costs nothing to negotiate at origination and everything to not have at month eleven.

The two structures worth comparing here are a cure-and-subrogation play versus a passive run-to-sale, because the answer changes depending on what state this foreclosure is happening in. In a judicial foreclosure state, the gap lender has months on the clock after a notice of default, which makes funding the cure defensible if the subrogation right is documented at the moment of the wire, the cure amount is tracked as a senior obligation, and the lender files a lis pendens or takes whatever step preserves that subrogation position under local law. In a non-judicial state, the cure window can be six to eight weeks total, and by the time the gap lender found out with half the period gone, wiring cure funds into a loan the senior can accelerate again the following month is a reasonable choice only if the lender is simultaneously negotiating a payoff or pushing the borrower to close that refi early. The cure option is not a hold strategy, it is a time-buying strategy, and it only works if the exit is already moving.

The passive run-to-sale math at 390k value sounds survivable until you add it up: 310k senior balance, foreclosure legal fees that on a contested matter can run 15 to 25k, accruing default interest on the senior note at whatever penalty rate is in that paper, and any property preservation costs the senior advances and adds to the balance. That buffer shrinks from 80k toward 40k or less before the sale date, and foreclosure sales rarely clear appraised value on a mid-rehab property. The 390k was an in-progress number, which means a distressed sale on an incomplete asset. What was the rehab completion percentage at the point the senior called the note, and was the 390k a certified appraisal or the borrower's estimate?

@the_original_poster what state was this in, because the cure period length changes everything here. In Michigan a junior can sometimes move faster than people expect if they know the timeline, but in states with longer statutory redemption periods the gap lender might actually have had room they did not use. The detail that does not come up until it bites someone is the senior's fee accrual during foreclosure, which in hard money land can run two to four points plus default interest on top of the note rate, and that math can flip a viable equity cushion into a deficiency in six to eight weeks on a 310k balance. The 390k valuation at month 11 mid-rehab is also doing a lot of work, because that number is almost certainly an as-complete or mid-construction estimate, not what a foreclosure sale generates against a room full of distressed buyers. Sixty thousand in second position with no notice right and no standstill is essentially an unsecured bet on the borrower's execution and the senior lender's patience, and clearly one of those failed.